MedisourceRx
Contact pharmacy ↗ Request an introduction ↗A 503B outsourcing facility owned by Hims & Hers that compounds injectable semaglutide — and the subject of a December 2025 FDA warning letter.
This profile is editorial. PeptideWellness has no commercial relationship with this pharmacy; coverage and assessment are never for sale.
MedisourceRx is unusual in this directory: it’s a compounding facility owned by a telehealth company. It’s the clearest example of vertical integration in compounded GLP-1s — the brand that sells the prescription also owns the pharmacy that fills it.
Facility & ownership
MedisourceRx is a 503B outsourcing facility in Los Alamitos, CA, listed on the FDA Registered Outsourcing Facilities list [1]. Hims & Hers acquired it in 2024: per the company’s SEC filing, “we acquired Seaview Enterprises, LLC (d/b/a MedisourceRx)… a licensed 503B compounding outsourcing facility, which compounds products primarily for Hims & Hers customers” [2]. So it is a Hims-owned subsidiary, not an independent third-party pharmacy. We could not confirm PCAB accreditation in ACHC’s registry.
What they compound
Injectable compounded semaglutide, produced primarily for Hims & Hers’ weight-loss customers [2]. (Hims’ oral compounded semaglutide is filled by a separate pharmacy, Strive.)
Regulatory record
MedisourceRx received an FDA warning letter dated December 12, 2025 [3]. Per FDA, the letter centered on failures in adverse-event reporting requirements for the facility. A warning letter is a formal FDA enforcement notice over significant violations. Stated as FDA’s findings. The FDA posted a close-out letter dated July 27, 2026, meaning it has evaluated MedisourceRx’s corrective actions and considers the matters in the warning letter addressed.
The read
Worth knowing for anyone using Hims’ injectable GLP-1: the pharmacy behind it is Hims itself, and it received an FDA warning letter in December 2025, since closed out. This isn’t a pharmacy consumers choose directly — it’s the in-house supplier for one telehealth brand — but it’s the sharpest illustration of how telehealth compounded-GLP-1 supply is becoming vertically integrated.
References
- FDA — Registered Outsourcing Facilities (503B) list. (accessed 2026-07-04)
- Hims & Hers Health, Inc. — Form 10-K (FY2024), acquisition of Seaview Enterprises, LLC (d/b/a MedisourceRx). (accessed 2026-07-04)
- FDA — Warning Letter to MedisourceRx (#717970, 2025-12-12). (accessed 2026-07-04)